Further investigations are necessary to evaluate the potential role of Cdk4/6 and PI3K pathway inhibitor combinations for treating breast cancer, at the same time, we are reporting the first use of Cdk4/6 and PI3K inhibitors in NPC model. Here, PIK3CA is linked to breast cancer.